Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts

General Physiology and Biophysics

Volumn 30, Issue 1, 2011, Pages 34-44

  Barakat, Ghinwa M ^a   Nuwayri Salti, Nuha ^a   Kadi, Lina N ^a   Bitar, Khalil M ^a   Al Jaroudi, Wael A ^b   Bikhazi, Anwar B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

Binding affinity; Dipeptidyl peptidase IV inhibitor; Dissociation constant; Exendin 4; Glucagon like peptide 1

Indexed keywords

BOVINE INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; IODINE 125; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CARDIOMYOCYTE; CONTROLLED STUDY; CORONARY ENDOTHELIUM; DISSOCIATION CONSTANT; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE; HEART PERFUSION; HISTOLOGY; IMMUNOFLUORESCENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; RAT; RECEPTOR BINDING; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; HEART; INSULIN; MALE; MYOCYTES, CARDIAC; PEPTIDES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR CROSS-TALK; RECEPTORS, GLUCAGON; VENOMS; VENTRICULAR REMODELING;

RATTUS;

EID: 79953702801     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/gpb_2011_01_34     Document Type: Article

References (33)

1. Asmar M., Holst J. J. (2010): Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr. Opin. Endocrinol. Diabetes Obes. 17, 57-62
2. Berghofer P., Peterson R. G., Schneider K., Fehmann H. C., Goke B. (1997): Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 46, 261-267 doi:10.1016/S0026-0495(97)90251-1 (Pubitemid 27106782)
3. Berthiaume N., Claing A., Regoli D., Warner T. D., D'Orleans-Juste P. (1995): Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. Br. J. Pharmacol. 115, 1319-1325
4. Bikhazi A. B., Khalifeh A. M., Jaroudi W. A., Saadeddine R. E., Jurjus A. R., El-Sabban M. E. (2003): Endothelin-1 receptor subtypes expression and binding in a perfused rat model of myocardial infarction. Comp. Biochem. Physiol. C, Pharmacol. Toxicol. 134, 35-43
5. Bose A. K., Mocanu M. M., Carr R. D., Brand C. L., Yellon D. M. (2005): Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54, 146 doi:10.2337/diabetes.54.1.146
6. Brunton S. (2009): Beyond glycemic control: treating the entire type 2 diabetes disorder. J. Postgrad. Med. 121, 68-81 doi:10.3810/pgm.2009.09.2054
7. Combettes M. M. (2006): GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr. Opin. Pharmacol. 6,1-8 doi:10.1016/j.coph.2006.08.003
8. D'Alessio D. A., Vahl T. P. (2004): Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am. J. Physiol. Endocrinol. Metab. 286, 882-890 doi:10.1152/ajpendo.00014.2004
9. Drucker D. J. (2003): Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26, 2929-2940 doi:10.2337/diacare.26.10.2929
10. Drucker D. J. (2007): Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 30, 1335-1343 doi:10.2337/dc07-0228
11. During M. J., Cao L., Zuzga D. S., Francis J. S., Fitzsimons H. L., Jiao X., Bland R. J., Klugmann M., Banks W. A., Drucker D. J., Haile C. N. (2003): Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. J. Nat. Med. 9, 1173-1179 doi:10.1038/nm919
12. 2+ Influx through L-type voltage-gated calcium mediate raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells. J. Biol. Chem. 277, 48146-48151 doi:10.1074/jbc.M209165200
13. Haddad R. E, Jurjus A. R., Ibrahim M. Z., Nahle Z. A., el-Kasti M. M., Bitar K. M. (1997): Binding of 125I-insulin on capillary endothelial and myofiber cell membranes in normal and streptozotocin-induced diabetic perfused rat hearts. Comp. Biochem. Physiol. a Physiol. 117, 523-530
14. Halimi S. (2008): DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Diabetes Metab. 34, 91-95 doi:10.1016/S1262-3636(08)73400-1
15. Hantouche C. M., Bitar K. M., Nemer G. M., Obeid M. Y., Kadi L. N., Der-Boghossian A. H., Bikhazi A. B. (2010): Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts. Can. J. Physiol. Pharmacol. 88, 54-63 doi:10.1139/Y09-095
16. Iltz J. L., Baker D. E., Setter S. M., Keith C. R. (2006): Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin. Ther. 28, 652-665 doi:10.1016/j.clinthera.2006.05.006
17. Inzucchi S. E., McGuire D. K. (2008): New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117, 574-584 doi:10.1161/CIRCULATIONAHA.107.735795
18. Karam C. N., Nuwayri-Salti N., Usta J. A., Zwainy D., Bitar K. M., Bikhazi A. B. (2005): Effect of systemic insulin and angiotensin II receptor subtype-1 antagonist on endothelin-1 receptor subtype(s) regulation and binding in diabetic rat heart. Endothelium 12, 225-231 doi:10.1080/10623320500476450 (Pubitemid 43771806)
19. Maiese K., Morhan S. D., Chong Z. Z. (2007): Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res. 4, 63-71 doi:10.2174/156720207779940653
20. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H. (2008): Chronic administration of alogliptin, a novel, potent and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur. J. Pharmacol. 588, 325-332 doi:10.1016/j.ejphar.2008. 04.018
21. Murphy K. G., Bloom S. R. (2007): Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes? Proc. Natl. Acad. Sci. U.S.A. 104, 689-690 doi:10.1073/pnas.0610679104
22. Nikolaidis L. A., Elahi D., Shen Y. T., Shannon R. P. (2005): Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, 2401-2408 doi:10.1152/ajpheart.00347.2005
23. Poretsky. L. (2002): Principles of Diabetes Mellitus. London, Kluwer Acedemic Publishers.
24. Porte D. J., Sherwin R. S., Baron A. (2003): Ellenberg& Rifkin's Diabetes Mellitus. Sixth ed., McGraw-Hill, USA
25. Scott K. A., Moran T. H. (2007): The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, 983-987 doi:10.1152/ajpregu.00323.2007
26. Seino S., Takahashi H., Fujimoto W., Shibasaki T. (2009): Roles of cAMP signaling in insulin granule exocytosis. Diabetes Obes. Metab. 4, 180-188 doi:10.1111/j.1463-1326.2009.01108.x
27. Sokos G. G., Nikolaidis L. A., Mankad S., Elahi D., Shannon R. P. (2006): Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12, 694-699 doi:10.1016/j.cardfail.2006.08.211
28. Tahara A., Matsuyama-Yokono A., Nakano R., Someya Y., Hayakawa M., Shibasaki M. (2009): Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice. Pharmacology 83, 177-187 doi:10.1159/000196813
29. Underwood C. R., Garibay P., Knudsen L. B., Hastrup S., Peters G. H., Rudolph R., Reedtz-Runge S. (2010): Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723-730 doi:10.1074/jbc.M109.033829
30. Vila Petroff M. G., Egan J. M., Wang X., Sollott S. J. (2001): Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ. Res. 89, 445-452 doi:10.1161/hh1701.095716
31. Wei Y., Mojsov S. (1995): Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358, 219-224 doi:10.1016/0014- 5793(94)01430-9
32. Yamamoto H., Lee C., Marcus J. N., Williams T. D., Overton J. M., Lopez M. E., Hollenberg A. N., Baggio L., Saper C. B., Drucker D. J., Elmquist J. K. (2002): Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110, 43-52
33. Yusta B., Baggio L. L., Estall J. L., Koehler J. A., Holland D. P., Li H., Pipeleers D., Ling Z., Drucker D. J. (2006): GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell. Metab. 4, 391-406 doi:10.1016/j.cmet.2006.10.001